Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%

  • Solid Biosciences Inc SLDB is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003.
  • In addition, the Company plans to narrow Research & Development activities to those related to SGT-001, SGT-003, and next-generation capsids.
  • Related: Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial.
  • Due to the reorganized pipeline, the Company will slash its headcount by 35% and plan to extend its current funds through mid-2024.
  • Solid Biosciences ended the March quarter with a cash balance of $180.1 million.
  • COO Joel Schneider will leave the Company at the end of May to become CEO of a private gene therapy biotech.
  • Solid has concluded enrollment in IGNITE DMD Phase 1/2 trial for SGT-001 and will continue monitoring dosed patients for five years post-treatment. The Company currently expects to continue dosing with SGT-001 in 2023.
  • The Company remains on track for an early 2023 IND submission for SGT-003.
  • Price Action: SLDB shares are down 13.8% at $0.67 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!